Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumannii

被引：41

作者：

Choi, JY

Park, YS

Cho, CH

Park, YS

Shin, SY

Song, YG

Yong, D

Lee, K

Kim, JM

机构：

[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul 120752, South Korea

[2] Yonsei Univ, Coll Med, AIDS Res Inst, Seoul 120752, South Korea

[3] Yonsei Univ, Coll Med, Dept Lab Med, Seoul 120752, South Korea

[4] Yonsei Univ, Coll Med, Res Inst Bacterial Resistance, Project Med Sci BK21, Seoul 120752, South Korea

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2004年 / 10卷 / 12期

关键词：

Acinetobacter baumannii; imipenem; sulbactam; synergy;

D O I：

10.1111/j.1469-0691.2004.00987.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The interaction between sulbactam and imipenem was evaluated with four clinical isolates of Acinetobacter baumannii, including two isolates resistant to imipenem, one of which produced IMP-1 metallo-p-lactamase. Two isolates (one of which was imipenem-resistant) were sulbactam-resistant by undefined mechanisms. MICs were determined by standard broth microdilution methods. Time-kill assays with imipenem and sulbactam, alone or in combination at 0.5 x MIC and 1 x MIC, showed a synergic effect in all four isolates of A. baumannii after incubation for 0, 4, 8 and >24 h at 35degreesC.

引用

收藏

页码：1098 / 1101

页数：4

相关论文

共 17 条

[1] Acinetobacter spp, as nosocomial pathogens: Microbiological, clinical, and epidemiological features [J].

BergogneBerezin, E ;

Towner, KJ .

CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (02) :148-+

[2] Bacteremia due to Acinetobacter baumannii epidemiology, clinical findings, and prognostic features [J].

Cisneros, JM ;

Reyes, MJ ;

Pachon, J ;

Becerril, B ;

Caballero, FJ ;

GarciaGarmendia, JL ;

Ortiz, C ;

Cobacho, AR .

CLINICAL INFECTIOUS DISEASES, 1996, 22 (06) :1026-1032

[3] Nosocomial bacteremia due to Acinetobacter baumannii:: epidemiology, clinical features and treatment [J].

Cisneros, JM ;

Rodríguez-Baño, J .

CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (11) :687-693

[4] Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii [J].

Corbella, X ;

Ariza, J ;

Ardanuy, C ;

Vuelta, M ;

Tubau, F ;

Sora, M ;

Pujol, M ;

Gudiol, F .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (06) :793-802

[5] Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii [J].

Fernández-Cuenca, F ;

Martínez-Martínez, L ;

Conejo, MC ;

Ayala, JA ;

Perea, EJ ;

Pascual, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (03) :565-574

[6] The susceptibility of non-fermentative gram-negative bacilli to cefperazone and sulbactam compared with other antibacterial agents [J].

Fu, W ;

Zhu, DM ;

Wu, S ;

Hu, FP ;

Zhang, YY .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (04) :444-448

[7] PSEUDOMONAS-CEPACIA SUSCEPTIBILITY TO SULBACTAM [J].

JACOBY, GA ;

SUTTON, L .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :583-584

[8] In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain [J].

Ko, WC ;

Lee, HC ;

Chiang, SR ;

Yan, JJ ;

Wu, JJ ;

Lu, CL ;

Chuang, YC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (02) :393-395

[9] Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobacter species [J].

Lee, K ;

Chong, Y ;

Shin, HB ;

Kim, YA ;

Yong, D ;

Yum, JH .

CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (02) :88-91

[10] Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii [J].

Levin, AS ;

Barone, AA ;

Penço, J ;

Santos, MV ;

Marinho, IS ;

Arruda, EAG ;

Manrique, EI ;

Costa, SF .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1008-1011